Elena Diaz
Primary Care · Miramar, FLNPI 1669966388
Payments from drug & device makers
Across 130 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$579
- Boehringer Ingelheim$548
- Lilly USA, LLC$299
- Antares Pharma, Inc.$208
- AbbVie$131
- AstraZeneca$110
- plus $747 from 21 others
What the payments were for
- Food & beverage$2,623100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $579 |
| Boehringer Ingelheim | 22 | $548 |
| Lilly USA, LLC | 15 | $299 |
| Antares Pharma, Inc. | 9 | $208 |
| AbbVie | 8 | $131 |
| AstraZeneca(2 entities) | 5 | $110 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $59 |
| Novartis | 3 | $57 |
| Corcept Therapeutics | 2 | $53 |
| Amarin Pharma, Inc. | 3 | $52 |
| Astellas Pharma US Inc | 2 | $50 |
| Amgen(2 entities) | 3 | $49 |
| Halozyme Inc | 2 | $47 |
| Exact Sciences | 2 | $45 |
| GSK | 2 | $42 |
| Amneal Pharmaceuticals LLC | 2 | $40 |
| Hologic Sales And Service, LLC | 1 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Pfizer | 2 | $30 |
| Alkermes, Inc. | 1 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
| Abbott | 1 | $20 |
| Verity Pharmaceuticals Inc. | 1 | $16 |
| Tolmar, Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
How this compares
$2,623 in reported general payments places this provider in the 85th percentile of 725 primary care providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 33 | $33,475 |
| TrulicityDulaglutide | 13 | $21,438 |
| FarxigaDapagliflozin Propanediol | 20 | $15,730 |
| Losartan Potassium | 50 | $713 |
| Metformin Hcl | 52 | $501 |
| Amlodipine Besylate | 54 | $453 |
| Rosuvastatin Calcium | 40 | $436 |
| Testosterone Cypionate | 14 | $419 |
| Atorvastatin Calcium | 55 | $412 |
| Levothyroxine Sodium | 39 | $373 |
| Escitalopram Oxalate | 16 | $282 |
| Zolpidem Tartrate | 19 | $259 |
| Nifedipine ErNifedipine | 11 | $233 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $208 |
| Gabapentin | 12 | $175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $299 | $54,91346 claims |
| AstraZenecaFarxiga | $110 | $15,73020 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $40 | $37339 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 725 primary care providers in Florida.
Other primary care in Miramar
- Paul ChanOrlando$447K
- Jenny WestPensacola$80K
- Maria Rodriguez ReyesHialeah$31K
- Railet RodriguezAltamonte Springs$14K
- Kevin HanawayFort Lauderdale$12K
- Kelly ChewningAlachua$11K
- Yolanda PalmeroSaint Cloud$11K
- Erica ClarkCitrus Springs$11K
- Michelle SelvaggiLakewood Ranch$10K
- Kristen DeasonTallahassee$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.